Laboratorios Richet S.A. has new and modern facilities authorized by ANMAT (the Argentine pharmaceutical authority). Their 11,000 square meters of manufacturing facilities were designed following the Good Manufacturing Practices (GMP) guidelines of international regulatory authorities to comply with the requirements of the international pharmaceutical audit organisms.
In 2021, Laboratorios Richet has opened an 8,000 square meters modern plant
for the production of general injectables and oral solids: injectable solutions in vials and ampoules, sterile and lyophilized powders, and large volume intravenous solutions; tablets, film-coated tablets, extended-release tablets and capsules.
The cutting edge equipment, with automated controls, guarantees compliance with the highest international standards. The new lyophilization equipment strengthens the experience of Laboratorios Richet in the market of lyophilized products, achieving high-quality medicines.
Its traditional 3,000 square meters plant is exclusively dedicated to the manufacturing of beta-lactam antibacterials in oral and injectable dosage forms.
Laboratorios Richet S.A. is a company in constant expansion due to its bet on technology renewal and investment in research and development at the service of health. This way, it has gone through its first 60 years offering affordable high-quality medicines to all of Latin America.